ArticleJTCVS open2026
Hypothermic perfusion protocol development for donor heart preservation.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objective: Hypothermic perfusion has been introduced for donor heart storage for ∼9 hours. However, opportunities exist to further define the optimal physiological conditions for a more prolonged period with 18 hours of preservation. In particular, the utility of exogenous cellular therapies such as administration of mitochondria are unknown in this setting. Methods: We examined several key aspects of the protocol for hypothermic perfusion of the donor heart. Yorkshire pigs hearts were used for perfusion with histidine-tryptophan-ketoglutarate (HTK) solution at ∼8 °C for 18 hours under different conditions followed by reanimation with normothermic perfusion for 3 hours. Results: HTK perfusate oxygenation was associated with worse contractility (Max dP/dt 630.38 ± 376.63 mm Hg/s vs 1101.80 ± 338.93 mm Hg/s, Conclusions: Avoidance of excess oxygenation, use of fresh HTK, antegrade cardioplegia delivery, as well as delivery of stored frozen mitochondria are key for the success of greatly prolonged hypothermic cardiac perfusion preservation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.